Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential

– All doses of REL-1017, including the maximum tolerated dose, demonstrated a statistically significant difference in abuse potential vs. ketamine (p-values <0.05)

– All doses of REL-1017, including the maximum tolerated dose, were statistically equivalent to placebo (p-values <0.05) 

– Company to host conference call at 8:30 AM Eastern Time today, February 23, 2022 

See more here